AI assistant
Sending…
AFT PHARMACEUTICALS LIMITED — Director's Dealing 2017
Jun 18, 2017
64327_rns_2017-06-18_20048211-4468-426d-9ab4-c036891e8f0f.pdf
Director's Dealing
Open in viewerOpens in your device viewer
==> picture [109 x 26] intentionally omitted <==
Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
| ToNZX Limited; and | AFT Pharmaceuticals Limited(AFT) 19-Jun-17 22-Dec-15 Jon Lamb AFT Pharmaceuticals Limited(AFT) Not applicable Director Fully-Paid OrdinaryShares in AFT Power to control the exercise of the right to vote as trustee of the Rivers One Trust which holds the sharesin Rivers OneLimited 201,305 207,972 Rivers OneLimited Rivers OneLimited 1 16-Jun-17 Allotment of new Ordinary Shares pursuant to Share Purchase Plan Not applicable NZ$2.25per share 6,667 No Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable |
AFT Pharmaceuticals Limited(AFT) 19-Jun-17 22-Dec-15 Jon Lamb AFT Pharmaceuticals Limited(AFT) Not applicable Director Fully-Paid OrdinaryShares in AFT Power to control the exercise of the right to vote as trustee of the Rivers One Trust which holds the sharesin Rivers OneLimited 201,305 207,972 Rivers OneLimited Rivers OneLimited 1 16-Jun-17 Allotment of new Ordinary Shares pursuant to Share Purchase Plan Not applicable NZ$2.25per share 6,667 No Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable |
|
|---|---|---|---|
| Name of listedissuer: | |||
| Date this disclosuremade: | |||
| Date of last disclosure: | |||
| Directororsenior managergiving disclosure | |||
| Full name(s): | |||
| Name of listedissuer: | |||
| Name of related body corporate (ifapplicable): | |||
| Position heldin listedissuer: | |||
| Summary of acquisition or disposal of relevant interest (excluding specified derivatives) Class ofaffected quotedfinancialproducts: |
|||
| Class ofaffected quotedfinancialproducts: | Fully-Paid OrdinaryShares in AFT | ||
| Nature of the affected relevant interest(s): | Power to control the exercise of the right to vote as trustee of the Rivers One Trust which holds the sharesin Rivers OneLimited |
||
| For that relevant interest- | |||
| Number heldinclass before acquisitionordisposal: | 201,305 | ||
| Number heldinclass afteracquisitionordisposal: | 207,972 | ||
| Currentregisteredholder(s): | Rivers OneLimited | ||
| Registeredholder(s) once transfers areregistered: | Rivers OneLimited | ||
| Details of transactions giving rise to acquisition or disposal | |||
| Details of transactions giving rise to acquisition or disposal | |||
| Total number of transactions to which notice relates: | 1 | ||
| Date of transaction: | |||
| Nature of transaction: | |||
| Name of anyotherpartyorparties to the transaction(if known): | |||
| The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value,describe the consideration: |
|||
| Number of financialproducts to which the transaction related: | |||
| If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include thefollowing details— |
|||
| Whether relevant interests were acquired or disposed of duringa closedperiod: | No | ||
| Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period: |
Not applicable | ||
| Date ofthe prior writtenclearance (ifany): | Not applicable | ||
| Summary of other relevant interests after acquisition or disposal: Class ofquoted financialproducts: Nature of relevant interest: For that relevant interest,- Number held in class: Current registered holder(s): For a derivative relevant interest,- Type of derivative: Details of derivative,- |
|||
| Not applicable | |||
| The notional value of the derivative (if any) or the notional amount of underlying financial products (ifany): |
Not applicable | ||
| Astatement as towhetherthe derivativeis cashsettled orphysically settled: | Not applicable | ||
| Maturity date ofthe derivative (ifany): | Not applicable | ||
| Expiry date ofthe derivative (ifany): | Not applicable | ||
| The price's specified terms (ifany): | Not applicable | ||
| Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financialproducts: |
Not applicable | ||
| _For that derivative relevant interest,- _ | |||
| Parties to the derivative: | Not applicable | ||
| If the director or senior manager is not a party to the derivative, the nature of the relevant interestinthe derivative: |
Not applicable |
Certification
I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.
Signature of director or officer:
Date of signature:
==> picture [49 x 59] intentionally omitted <==
==> picture [490 x 48] intentionally omitted <==
19-Jun-17
More from AFT PHARMACEUTICALS LIMITED
Notice of Dividend Amount
2026
May 25
Regulatory Filings
2026
May 24
Notice of Dividend Amount
2026
May 21
Share Issue/Capital Change
2026
May 21
Earnings Release
2026
May 20
Earnings Release
2026
May 20
Investor Presentation
2026
May 20
Annual Report
2026
May 20
Notice of Dividend Amount
2026
May 20
Board/Management Information
2026
May 17